Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives $62.83 Consensus Price Target from Brokerages

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has received an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $62.8333.

Several research analysts recently issued reports on the stock. Zacks Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 6th. Cantor Fitzgerald boosted their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Sit Investment Associates Inc. grew its stake in Supernus Pharmaceuticals by 0.4% in the 4th quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock valued at $3,240,000 after acquiring an additional 250 shares during the last quarter. Summit Global Investments lifted its holdings in shares of Supernus Pharmaceuticals by 6.1% in the first quarter. Summit Global Investments now owns 4,436 shares of the specialty pharmaceutical company’s stock valued at $229,000 after purchasing an additional 256 shares in the last quarter. Maryland State Retirement & Pension System lifted its holdings in shares of Supernus Pharmaceuticals by 3.6% in the fourth quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock valued at $415,000 after purchasing an additional 290 shares in the last quarter. SummitTX Capital L.P. grew its position in shares of Supernus Pharmaceuticals by 2.7% in the fourth quarter. SummitTX Capital L.P. now owns 11,670 shares of the specialty pharmaceutical company’s stock valued at $580,000 after purchasing an additional 303 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in shares of Supernus Pharmaceuticals by 2.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 14,548 shares of the specialty pharmaceutical company’s stock worth $752,000 after purchasing an additional 321 shares in the last quarter.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock opened at $43.73 on Monday. Supernus Pharmaceuticals has a 12 month low of $42.45 and a 12 month high of $59.68. The business has a 50 day simple moving average of $46.81 and a 200-day simple moving average of $48.66. The stock has a market capitalization of $2.54 billion, a PE ratio of -22.78, a price-to-earnings-growth ratio of 0.81 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The firm had revenue of $219.06 million during the quarter, compared to analysts’ expectations of $205.31 million. During the same quarter last year, the business earned $0.40 earnings per share. The business’s quarterly revenue was up 32.4% on a year-over-year basis. As a group, equities research analysts anticipate that Supernus Pharmaceuticals will post 1.97 EPS for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.